← Back to Clinical Trials
Recruiting Phase 1 NCT06136195

NCT06136195 Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06136195
Status Recruiting
Phase Phase 1
Sponsor Yale University
Condition Alcohol Consumption
Study Type INTERVENTIONAL
Enrollment 63 participants
Start Date 2024-07-01
Primary Completion 2026-05-31

Trial Parameters

Condition Alcohol Consumption
Sponsor Yale University
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 63
Sex ALL
Min Age 21 Years
Max Age 50 Years
Start Date 2024-07-01
Completion 2026-05-31
Interventions
Mavoglurant

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this research study is to find out about the effects of a drug called mavoglurant on alcohol consumption.

Eligibility Criteria

Inclusion Criteria: 1. Ages 21-50 (The lower limit is to avoid offering alcohol to individuals below the drinking age of 21. The upper age is determined by experience recruiting for our prior studies). 2. Ability to read English at 6th grade level or higher. 3. Meet DSM-V criteria for moderate or severe Alcohol Use Disorder (AUD). 4. Average weekly alcohol consumption of 30-70 standard drinks for men and 20-65 drinks for women. The lower limits are consistent with the lower sex-specific cut-offs defining high-risk drinking based on World Health Organization Risk Levels (WHO, 2000); the upper limits are designed to avoid recruiting participants whose drinking is likely to exceed the number of drinks available in the Alcohol Drinking Paradigm (ADP). Exclusion Criteria: 1. Individuals who are seeking alcohol treatment or have been in alcohol treatment within the past 6 months. 2. Meet current Diagnostic and Statistical Manual v.5 (DSM-V) criteria for substance use disorder, except for tob

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology